Physician profile
Robert B Imani
NPI 1639374747
$10,808.76
in general payments reported to CMS, 2019-2025
26 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,722 · 2020: $932 · 2021: $1,149 · 2022: $1,343 · 2023: $1,667 · 2024: $1,544 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,572 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,571.62 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,932.74 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,294.18 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,087.22 | 2019-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $796.31 | 2019-2022 | |
| Ptc Therapeutics, INC. | $774.35 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $677.31 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $527.09 | 2019-2022 | |
| Neuronetics, INC. | $495.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $460.82 | 2019-2023 | Spravato |
| Abbvie INC. | $454.54 | 2021-2025 | |
| Alkermes, INC. | $396.27 | 2021-2025 | Aristada, Lybalvi |
| Allergan, INC. | $390.87 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $357.06 | 2022-2024 | Austedo Xr, Austedo |
| Ironshore Pharmaceuticals INC. | $189.86 | 2019 | |
| Axsome Therapeutics, INC. | $183.95 | 2023-2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $182.81 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $167.35 | 2025 | Cobenfy |
| Eisai INC. | $114.99 | 2021 | |
| Supernus Pharmaceuticals, INC. | $112.85 | 2022-2024 | Qelbree |
| Neurocrine Biosciences, INC. | $99.61 | 2023-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.33 | 2022 | |
| Arbor Pharmaceuticals, INC. | $30.26 | 2019-2021 | |
| Neos Therapeutics, LP | $22.24 | 2025 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $16.30 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Imani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.